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Spontaneous prostate cancer (PCA) is known to occur only in humans and in dogs. The disease occurs at advancing age in both species and, similar to late stage PCA in humans, canine prostate tumors are able to grow in an androgen-depleted environment.
Serum concentrations of androgens may explain the racial differences in PCA risk in humans. Earlier studies suggest that higher testosterone levels in the Bouvier des Flandres may explain the eight times higher risk of developing PCA in this species. 
In humans, shorter CAG repeat lengths in the androgen receptor gene have been linked to a higher chance of developing prostate cancer.  In dogs, shorter CAG repeat lengths also seem to be associated with a higher chance of developing PCA.
In present study, blood samples were taken from 49 Bouviers des Flandres and 44 control dogs. Concentrations of testosterone, DHT and androstenedione were measured using radio immunoassay kits. From the bouviers an other blood sample was taken from which DNA was amplified with a PCR and the product was analyzed with a Genescan to determine CAG repeat lengths. 
Aim of our study was to investigate the relationship between repeat length and testosterone levels in Bouviers, the differences in androgen levels between Bouviers and control dogs, the relationships between androgens and age and the relations between the different androgens. Furthermore it was investigated if higher testosterone levels in the Bouviers des Flandres are hereditary through pedigree research.
Our results show no significant difference in androgen levels between the bouviers and the control group. This suggests that different androgen levels do not explain the breed related difference in the risk of developing PCA between bouviers and other species. We also did not find evidence that having high or low testosterone levels in bouviers is hereditary. Most striking finding in this study is that the relationship between testosterone and androstenedione is stronger in bouviers then in the control group. Whether this is due to a shift in production of androstenedione to the testis, remains to be investigated.










Human and canine prostate cancer
Prostate cancer (PCA) is one of the most important malignancies in men in western countries (Feldman, 2001). In elderly men PCA at autopsy has been reported to exceed 40% (Winters et al., 2001). Apart from humans, dogs are the only species in which spontaneous prostate cancer occurs (Waters et al., 1997). In dogs however, it appears to be a very rare disease. Necropsy studies have shown a prevalence of between 0,2% and 0,6 % (Bell et al, 1991). Another important difference between the two species is that canine prostate cancer occurs with a relatively high frequency in castrated animals (Teske et al., 2002), whereas PCA rarely occurs in eunuchs (Wilding, 1997). Apart from these differences, the diseases in the two species share some striking similarities. Prostatic intraepithelial neoplasia (PIN) has been found in both species. PIN has been recognized as a pre-cursor of PCA in humans (Waters and Bostwick, 1997, Leav et al., 2001, Aquilina et al., 1998). In dogs PIN is seen in 66-72% of dogs with PCA. Castrated dogs have a much lower frequency of PIN (8%) compared to sexually intact dogs (55%) (Waters and Bostwick, 1997). Castrated dogs however have a 3.4 times higher risk of developing PCA compared to sexually intact dogs (Bell et al., 1991, Teske et al., 2002), which makes it highly unlikely that PIN is a precursor of PCA in dogs. The disease occurs frequently at advancing age in both humans and dogs. In dogs the age at diagnosis has been reported to range from five to seventeen years (median age of ten years) (Krawiec et al., 1992). Pulmonary and bone metastases are common in both species. The lumbar vertebrae and pelvis are most frequently affected in dogs with bone metastasis (Johnston et al., 2000). Canine prostate tumors are able to grow in an androgen-depleted environment, similar to late stage prostate cancer in men.
Similar to late stage human prostate cancer, no adequate therapy exists today for its androgen-independent canine counterpart (Bell et al., 1991, Johnston et al., 2000, Teske et al., 2002). Castration leads to a decrease in non- neoplastic tissue while the neoplastic tissue is not affected. Radical prostactomy is a relatively safe therapeutic option in clinically localized prostate cancer in humans. In dogs, surgical removal of the prostate is not recommended because it often leads to urinary incontinence.  

Androgens and prostate cancer
Androgens play an important role in the normal growth and function of the prostate. Androgen production is regulated by the hypothalamic-pituitary-gonadal axis (Debes et al., 2002). The main circulating hormone is testosterone, synthesized in the Leydig cells of the testis (Soronen et al., 2004). In prostate cells, testosterone is converted to dihydrotestosterone (DHT) by 5-alpha-reductase. Both hormones can bind to the androgen receptor in the nucleus. However, DHT forms a more stable receptor-ligand complex, which is 3-10 times more potent. Once the androgen binds to the androgen receptor (AR) it enters an active state and undergoes transactivation. The main function of the androgen receptor is to induce growth of the male urogenital structures (Debes et al., 2002). Testosterone and DHT can also be formed peripherally from androstenedione, which is produced in the adrenal cortex (Chastain et al., 1986).
Plasma levels of androgens show variations between different populations, which may explain differences in PCA susceptibility between these populations. African-American men have a twofold higher PCA risk compared to European-Americans. African-Americans also have approximately 15% higher levels of total testosterone compared to the Caucasian population (Debes et al., 2002, Winters et al., 2001). In dogs, breed related differences in the occurrence of PCA have been found as well. The Bouviers des Flandres appears to have an eight times higher risk of developing PCA compared to other breeds (Teske et al., 2002). There are many factors, such as differences in nutrition, differences in detection of PCA and genetic differences, which may explain the difference in PCA risk in men (Bostwick et al., 2004). In dogs however only the genetic factor may explain the breed-related difference in PCA occurrence since there are no breed-related differences in nutrition and veterinary treatment in the Netherlands.
Earlier studies have shown that total testosterone levels as well as DHT levels are significantly higher in Bouviers des Flandres than in other dogs. It is suggested that higher testosterone levels in the Bouviers des Flandres may be positively correlated to the higher risk of developing PCA (van der Meijden, 2006).

Androgen receptor and prostate cancer
The AR plays a major role in the development and function of normal and malignant prostate cells. The AR is expressed in nearly all prostate cancers (Culig et al., 2002). 
The AR is a ligand-activated transcription factor and a member of the nuclear receptor family. Like other nuclear receptors it consists of an amino-terminal transcription activation domain, a DNA-binding domain and the carboxy-terminal ligand binding domain. The DNA binding domain is separated from the ligand binding domain by a hinge region. After ligand binding the AR undergoes a transformation witch allows binding of importins witch allow the AR to be translocated from the cytoplasm to the nucleus. After entering the nucleus the AR interacts with other transcriptional mediators and co-factors and modulates target gene transcription (Chatterjee B, 2003).

In Humans with PCA, androgen withdrawal or peripheral blockage of androgen action still are important therapeutic options. However, after initial regression the PCA often returns in an androgen independent form. When the tumor relapses the treatment is prostatectomy or irradiation. Different pathways for the development of androgen refractory prostate cancer have been recognized. Important pathways bypassing the AR are the deregulation of apoptotic genes and the neuroendocrine differentiation of prostate cancer cells. Neuroendocrine cells secrete neuropeptides witch induce the growth of nearby cells. Neuroendocrine cells are found in 40-100% of the patients with androgen refractory PCA (Debes et al., 2004).




CAG-repeats and prostate cancer
The human AR gene is a 90-kilobase pair gene located on the x-chromosome and consisting of 8 exons which encode for the 4 domains on the AR (Chatterjee B, 2003). The transactivation domain is highly polymorphic and is encoded by exon 1. This domain contains three polyglutamine repeats of which two are polymorphic (CAG1 and CAG3) and one polyglycine repeat (Mishra et al., 2005; Hsing et al., 2000). Like humans, dogs have two polymorphic polyglutamine repeats. 
In vitro studies by Chamberlain et al. showed that the CAG repeat length is inversely correlated with the transactivation function of the AR. Together with the fact that a higher expression of AR in prostate cancer cells stimulate cancer cell proliferation and survival (Isaacs et al., 2004) this suggests a stimulating role of the androgen–AR axis in human PCA. 
Earlier studies have shown ethnic differences in CAG repeat lengths. In several studies a relationship has been found between CAG repeat length and the risk of prostate cancer in humans. In Indian, Brazilian and Hispanic men there has been found a correlation between shorter CAG repeats and the risk of PCA (Mishra et al., 2005; Silva Neto et al., 2008; Balic et al., 2002). Chinese men have longer repeat lengths then western men (Hsing et al., 2000). Hsing et al. also showed that in Chinese men a shorter CAG repeat length is correlated with a higher risk of clinically significant prostate cancer. A study by Gilligan et al. confirmed earlier reports (Nelson et al., 2002) that black men have shorter CAG repeat lengths than reported in white and Asian men. However this study did not show an increased risk of prostate cancer among black men with fewer CAG repeats (Gilligan et al.., 2004). Cude et al. found no correlation between CAG length and time to progression or overall survival time, but a significant correlation was found between Gleason score and CAG length suggesting that shorter CAG lengths may predict a higher histological grade of prostate cancer (Cude et al., 2002).

Objectives
Aim of this study is complementing data from earlier studies by Jagtenberg investigating the CAG repeat lengths in the Bouviers des Flandres and studies by van der Meijden investigating androgens in the Bouviers des Flandres. This data will be used to investigate the relationship between repeat length and testosterone levels in Bouviers, the differences in androgen levels between Bouviers and control dogs, the relationships between androgens and age and the relationships between testosterone, DHT and androstenedione in bouviers and the control group. 









Testosterone levels, androstenedione levels and CAG repeat lengths found in earlier studies at Utrecht University by van der Meijden (2006) and Jagtenberg (2005) were used and complemented with data from new blood samples. The data used from earlier studies consisted of testosterone and DHT levels and CAG repeat lengths of 22 intact male Bouviers des Flandres and 18 intact male dogs of different breeds. New blood samples were taken from 26 intact male Bouviers des Flandres and from 29 intact male dogs of various other breeds. These samples where taken in the period between May 2006 and September of the same year. All the blood samples were obtained from the jugular or cephalic vein. The dogs were either healthy dogs or presented to the clinic (Department of Clinical Sciences of Companion Animals, Faculty of Veterinary medicine, Utrecht University) for other conditions than prostatic disease. From the Bouviers 3-4 ml of blood was sampled in EDTA tubes and DNA was isolated using the salt extraction method according to Miller et al. (1988). Collected DNA was stored at 4°C. From all the dogs (Bouviers and controls) another 3-4 ml of blood were sampled and serum was stored at -20°C after centrifugation until hormone measurement. The data from 2 Bouviers and from 3 other dogs was not used because either the dog was too young or not enough material was sampled for al 3 hormone measurements. The final dataset that was used consisted of data from 49 Bouviers and 44 control dogs.
The owners of the Bouviers where asked to send in a copy of the pedigree of their dog(s). 26 copies where obtained and sorted. A pedigree was used if a relationship through only male ancestors with another Bouvier from the research group was found. The testosterone levels of the related Bouviers where compared.

Serum hormone measurements
The following serum hormones where measured: testosterone (T, produced by the testicles), Dihydrotestosterone (DHT, active form, after transformation of T in prostate), and androstenedione (precursor of estradiol and testosterone, produced in the adrenal glands). 

Total testosterone was measured using a Coat-A-Count solid phase radioimmunoassay kit obtained from the Diagnostic Products Corporation (Los Angeles, CA). The procedure follows the basic principle of radioimmunoassay whereby there is competition between a radioactive and a non-radioactive antigen for a fixed number of antibody binding sites. 125I-labeled hormone competes with the hormones in the patient sample for antibody sites. After incubation and separation of bound and free, the tubes are counted in a gamma counter (Chard, 1987).
Before the assay, 0,25 ml of serum samples were extracted with 1 ml ether. After extraction the aqueous phase was frozen and the ether extract was decanted, evaporated to dryness and dissolved in 0,25 ml of buffer PBS with 0,5% BSA.
The intra-assay coefficient of variation was 16,6% and the sensitivity was 0,14 nmol/l. The accuracy of the assay, measured by recovery, was 91,2%. Cross-reactivities were as follows: 4-estren-17-ol-3-one (20%), 11-ketotestosterone (16%), 5α-dihydrotestosterone (3,3%), 19-hydroxyandrostenedione (2%), methyltesterone (1,7%), and 4-estren-7x-methyl-17B-ol-3-one (1,1%).

Androstenedione was measured directly using a Coat-A-Count radioimmunoassay obtained from the Diagnostics Products Corporation (Los Angeles, CA).
The intra-assay coefficient of variation was 4,2% and the sensitivity was 0,14 nmol/l. The recovery was 101,5%. The cross-reactivities were as follows: testosterone (1,49%), dihydrotestosterone (0,212%), DHEA (0,164%), progesterone (0,160%) adrenosterone (0,135%). 

Dihydrotestosterone was measured after extraction using a radioimmunoassay kit (Intertech®), which is also a competitive immunoassay. From each serum sample 300 μl was extracted with 3 ml of diethylether. The tubes were vortexed for two minutes and then centrifuged at 2000 rpm for 5 minutes. The aqueous phase was frozen and the ether extract was decanted and evaporated to dryness. After adding PBS buffer, vortexing and adding 50 μl oxidation solution, the tubes where incubated at 37˚C for 20 minutes. The solution was extracted again with 3 ml mixture of hexane/ethanol 98/2. The tubes where then vortexed, centrifuged and 2 ml of the organic layer was transferred into glass tubes and evaporated to dryness.
The sensitivity of the assay was 0,07nmol/l. The cross-reactivities were as follows: estradiol (1,20%), estriol (0,04%), DES (<0,01%), pregnolone (<0,01%), progesterone (<0,01%), testosterone (<0,01%) and aldosterone (<0,01%)

Polymerase chain reaction (PCR)
The CAG repeat regions of the canine androgen receptor gene were amplified by performing a PCR, using 25 ng of genomic DNA in a final volume of 15 μl of the PCR-mixture described in Table 1.

Product	Volume (μl)	Concentration
10x PCR Gold Buffer	1,5	1x
MgCl2 (25mM)	1,5	2,5 mM
dNTP's (1mM)	3	0,2 mM
Primer with M13 tail (1μM)	0,45	0,03 μM
Primer (10 μM)	0,45	0,3 μM





Table 1: PCR Mixture

The PCR program of the MJ Cyclers started with a denaturing step at 95º Celsius for 5 minutes, followed by 10 cycles of three steps: a denaturing step at 95º Celsius for 30 seconds, an annealing step at annealing temperature for 15 seconds and an extension step at 72º Celsius for 30 seconds. Subsequently, 25 cycles of these steps were executed, the only exception was, the temperature for the denaturing being 92º Celsius. Finally, there was a 10 minute extension step at 72º Celsius, ending the program at room temperature.
A PCR with a temperature gradient was used on one DNA sample to determine the correct annealing temperature. For the first repeat, a temperature gradient varying from 50º to 60º Celsius was used, for the second repeat a gradient from 55º to 70º Celsius was used. The results of the gradients were analyzed on agarose gel.

Sequence analysis of the canine AR CAG repeat length











The serum androgen levels of Bouviers and control dogs are shown in Table 2 and in Figure 1. No significant difference was found in serum testosterone (p=0,623), androstenedione (p=0,867) or DHT (p=0,234) levels between the control group and the Bouviers.

	Testosterone (nmol/l)	Androstenedione (nmol/l)	DHT (nmol/l)
Mean total (n=93)	14,04 (SD 9,39)	5,19 (SD 5,37)	1,18 (SD 0,81)
Mean control (n=44)	13,49 (SD 9,98)	5,07 (SD 6,19)	1,08  (SD 0,87)
Mean Bouvier (n=49)	14,53 (SD 8,90)	5,30 (SD 4,57)	1,27 (SD 0,74)





Figure 1: Mean serum hormone concentrations in Bouviers and control dogs


Correlation between androgens and aging









Figure 3: correlation between serum Testosterone and DHT (nmol/l) 

A strong positive correlation was found between serum testosterone levels and serum DHT levels in the control group, the Bouviers and the whole group (p<0,01), as shown in Figure 3.

Relationships between Bouviers
In figures 4 through 9 relationships between Bouviers from the research group with a known pedigree are depicted. Squares are male dogs, circles are female dogs. Yellow stands for a high testosterone level (14 nmol/l or higher) and the green squares stand for a low testosterone level (lower than 14). A concentration of 14 nmol/l was chosen because earlier studies by van der Meijden suggested that Bouviers could be divided in a group with high testosterone levels and a group with low testosterone levels. In that study the median testosterone concentration in bouviers was 14 nmol/l. 






GF: Testosterone 5.62; Androstenedione 0.59
HN: Testosterone 11.56; Androstenedione 1.67









HE: Testosterone 1.60; Androstenedione 0.32
RO: Testosterone 1.67; Androstenedione 0.51








MO: Testosterone 21.60; Androstenedione 10.40
HA: Testosterone 2.60; Androstenedione 0.10








BS: Testosterone 17.00; Androstenedione 4.8
SX: Testosterone 14.00; Androstenedione 1.8








RA: Testosterone 21.00; Androstenedione 5.1
ENZ: Testosterone 11.00; Androstenedione 1.8
CAS: Testosterone 23.00; Androstenedione 3.2
GUI: Testosterone 13.00; Androstenedione 4.2









RR: Testosterone 4.60; Androstenedione 1.70
DL: Testosterone 11.00; Androstenedione 8.10
LD: Testosterone 3.40; Androstenedione 1.80






Figures 6 and 8 show differences in levels of testosterone in closely related animals. 










Androgens play an important role in the development of prostate cancer in humans. Racial differences in testosterone levels have been linked to differences in PCA susceptibility in humans. Bouviers have a higher risk of developing PCA than other breeds (Teske et al., 2002). Earlier studies by van der Meijden suggested that Bouviers had significantly higher levels of testosterone and DHT. They suggested that the higher testosterone levels could be associated with the higher risk of PCA in the Bouvier des Flandres. In this study, which complemented the same data used in the studies by van der Meijden, we did not find a significant difference in these hormone levels (testosterone p=0,623; androstenedione p=0,867; DHT =0,234).
The testosterone levels found in this study were higher then levels found in other studies. Like in our study, testosterone levels in other studies were highly variable. This can be explained by factors such as seasonal and environmental influences on testosterone levels as well as the circadian rhythm of the serum testosterone concentration. Testosterone levels found in a study by Rhodes et al. ranged from 6,88-14,2nmol/l. Ortega-Pacheco et al. found a mean testosterone level of 8,7 ± 3,6nmol/l. Mischke et al. found a mean testosterone level of 6,77nmol/l. Tsutsui et al. and Kawakami et al. found mean testosterone levels of 10,76 resp. 7,3nmol/l. 
The androstenedione levels we found were comparable with levels found in other studies. Frank et al. found a mean level of 7,85nmol/l (1,49-10,98).
The DHT levels found in this study were some what lower than levels found in a study by Rhodes et al. Rhodes et al. found DHT levels ranging from 1,31 to 2,63 nmol/l. 
Most canine prostate tumors are unresponsive to androgen depletion and castrated male dogs have a greater risk of developing prostate cancer than intact dogs (Johnston SD et al., 2000, Teske et al., 2002). Furthermore prostate tumors in castrated male dogs appear to be more aggressive and of a less differentiated type then in intact males. These findings could suggest a protective role of androgens in prostate cancer in dogs (Lai et al 2008). The findings in this study, however, cannot strengthen this hypothesis. 
In humans and in dogs, PCA occurs most frequently at an advanced age (Bell et al, 1995; Krawiec et al., 1992). Testosterone levels in men decrease after the age of 60 years. In our study no significant correlation between age and testosterone levels or age and DHT levels was found. Androstenedione and age however, were positively correlated in the control group and the group as a whole. This might be explained by the increased activity of the pituitary-adrenocortical axis in ageing dogs. In the Bouviers des Flandres however androstenedione levels were not significantly correlated to age. An explanation could be that the androstenedione production takes place more in the testis then in the adrenals in the bouvier.
Another striking finding in our study was that there seemed to be a stronger relationship between androstenedione and testosterone in the group of bouviers than in the control group. Androstenedione was positively correlated with testosterone and DHT in the bouvier group. We did not find a significant correlation between androstenedione and testosterone in the control group and the correlation between androstenedione and DHT was not as strong as in the group of the bouviers. The strong correlation between testosterone and androstenedione suggests that these hormones have a common source in the Bouvier. Taken in to account that leydig cells in the testis produce about 95% of the circulating testosterone this suggests that in the bouvier the androstenedione production takes place more in the testis then in the adrenals compared to the control group.
Several studies have shown environmental and seasonal influences on serum testosterone levels in dogs (Martins et al., 2006) and a circadian rhythm in serum testosterone levels (Fukuda et al., 1990). In our study only single blood samples were taken from the dogs over a period of a few months. These samples were not taken at a fixed time but randomly. Another critical point is that it is unknown if circulating hormone levels are an optimal indicator for intraprostatic levels. Especially circulating DHT may not be a good indicator of the intraprostatic DHT levels because DHT is also produced in several other organs like the liver, skin and testis. Another issue concerning the hormone levels is the large intra-assay variability of the testosterone radioimmunoassay and the intra-assay coefficient and the recovery of the DHT immunoassay which where not available.

In the study by van der Meijden it seemed there might be a dichotomy in bouviers concerning the testosterone levels. Their results suggested that the bouviers could be divided into two groups. A group of bouviers with high testosterone and a group with low testosterone divided at a testosterone level of about 14nmol/l. This suggested that having high or low testosterone for Bouviers is hereditary. By investigating pedigree records of the Bouviers and comparing there testosterone levels we found that it is unlikely that such a hereditary dichotomy exists. 
The same study tried to investigate the relationship between testosterone levels and CAG repeat length. In humans several studies have shown a correlation between CAG repeat length and the risk of developing PCA. This may explain the ethnic differences in the risk of PCA in humans. Short CAG repeats have been related to a higher transactivation activity of the androgen receptor gene. Whether this relation is present in dogs remains to be investigated. Furthermore a higher expression of AR in prostate cancer cells has been found to stimulate cancer cell proliferation and survival (Isaacs et al., 2004).
Like humans, rats and mice, the canine AR gene contains 3 polyglutamine repeats of which two are polymorphic. In humans no significant correlation was found between repeat length and testosterone levels (Shimbo et al., 2005). The results in the study by van der Meijden suggested that a short CAG repeat length was more common among the bouviers with lower testosterone levels. However the number of dogs was to low to find a significant relationship. In this study we tried to investigate this relationship by complementing the data van der Meijden used. The results however remain to be processed.
In conclusion the results of our study show no significant difference in androgen levels between the bouviers and the control group which can not explain the breed related difference in the risk of developing PCA. We also could not find evidence that having high or low testosterone levels in bouviers is hereditary.
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37	606736	Nova scotia duck tolling retriever	1,4	27	18	5,12
38	606570	Tibetan terrier	0,9	15	3,4	0,96
39	604228	Labrador Retriever	0,7	2,8	0,3	0,27
40	410018	Cesky Fousek	4,6	32	6,7	2,23
41	409506	Jack russel	6,9	16	1,3	1,12
42	605369	Jack Russel	6,7	20	4,3	1,32
43	606799	Crossbreed German shepherd	10,4	17	2,4	1,11
44	605447	Jack Russel	8,1	10	1,2	0,98
45	507210	Bouvier	8,8	6,85	11,52	0,66
46	506560	Bouvier	0,7	3,33	7,62	0,37
47	401512	Bouvier	2,8	21,6	10,4	1,69
48	409188	Bouvier	6,7	1,6	0,23	0,40
49	Rocket	Bouvier	3,6	1,67	0,51	0,53
50	Athos-Amis	Bouvier	6,4	26,66	6,84	1,74
51	205401	Bouvier	5,6	5,47	2,83	1,23
52	213820	Bouvier	7,0	11,3	4,87	1,11
53	212961	Bouvier	4,9	12,8	4,15	1,17
54	216119	Bouvier	9,6	8,75	4,06	0,82
55	411664	Bouvier	10,2	14,14	16,17	1,31
56	Baiko	Bouvier	1,9	8,27	5,98	1,04
57	Harco	Bouvier	2,4	11,56	1,67	1,20
58	Gamble	Bouvier	5,1	5,62	0,59	0,80
59	Sandor	Bouvier	6,0	7,72	4,77	0,92
60	411903	Bouvier	10,7	16,54	3,07	1,50
61	411318	Bouvier	7,9	26,75	4,77	1,95
62	505308	Bouvier	7,1	23,59	4,37	1,58
63	Boris	Bouvier	3,5	25,74	4,54	1,52
64	Borke	Bouvier	0,4	3,92	4,18	0,47
65	Scar	Bouvier	9,8	19,33	13,85	1,97
66	Urvinju	Bouvier	5,9	20,14	24,09	1,99
67	Jadon	Bouvier	1,6	26,68	10,58	4,41
68	Gabber	Bouvier	2,1	19,41	5,15	2,53
69	Jumbo	Bouvier	2,8	22	3,3	1,49
70	Bobo	Bouvier	11,3	0,1	0,1	0,02
71	Count	Bouvier	6,5	5,4	2	0,29
72	603712	Bouvier	6,3	45	9,1	1,74
73	603849	Bouvier	6,6	18	7,9	1,19
74	604032	Bouvier	10,2	24	11,4	1,79
75	Foggy	Bouvier	5,9	19	3,8	1,26
76	Rhodos	Bouvier	5,0	4,6	1,7	0,78
77	Damon	Bouvier	5,9	11	8,1	2,07
78	Casanova	Bouvier	1,3	23	3,2	1,03
79	Jesper	Bouvier	1,4	25	9,6	2,39
80	Sky	Bouvier	0,0	2,9	6,2	0,86
81	Rancho	Bouvier	3,6	21	5,1	1,46
82	Bica	Bouvier	10,4	14	3,4	2,46
83	Enzo	Bouvier	1,4	11	1,8	1,04
84	Guido	Bouvier	6,4	13	4,2	1,04
85	Chico Cheriline	Bouvier	3,5	18	2,7	1,41
86	Harley	Bouvier	5,1	14	1,8	1,09
87	Chico 	Bouvier	7,0	21	4,5	1,31
88	Boy	Bouvier	10,5	6,8	0,2	0,41
89	Bear	Bouvier	3,5	17	4,8	0,96
90	Sjors	Bouvier	4,9	14	1,8	0,98
91	Conan	Bouvier	6,0	10	1,7	0,85
92	Sailor	Bouvier	3,9	17	2,7	1,28
93	Rohan	Bouvier	1,9	2,6	0,1	0,31
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